Cationic [bis(1,3‐diethyl‐4,5‐diarylimidazol‐2‐ylidene)]Au(I) bromide complexes have demonstrated considerable potential as new antitumor agents. In order to investigate whether the gold is crucial for the antitumor activity, the imidazole ligands were connected by a methylene bridge. Biological evaluation revealed that bis[1,3‐diethyl‐4,5‐diarylimidazol‐2‐ylidene]methane compounds exhibited growth inhibition effects against mammary (MCF‐7 and MDA‐MB 231) and colon (HT‐29) carcinoma cell lines. In comparison with gold complexes, the methylene derivatives showed drastically reduced cell growth inhibitory properties. However, the growth of bacteria was significantly inhibited by bis[1,3‐diethyl‐4,5‐bis(4‐methoxyphenyl)imidazol‐2‐ylidene]methane dibromide (4) and opens a new application of this compound type.